LIBTAYO is a human IgG4 anti–PD-1 monoclonal antibody1

LIBTAYO was generated using VelocImmune® technology2

  • VelocImmune is a unique technology for producing human monoclonal antibodies3
  • Efficiently creates a large quantity of optimized antibody drug candidates3
  • Creates high-affinity antibodies to therapeutic targets3
Inactive T-cell resulting from the interaction of the PD-1 receptor on tumor cell
Tumor-immune evasion

T-cell inactivation can result from interaction of the PD-1 receptor on tumor-infiltrating T cells with its ligands, PD-L1 and PD-L2, expressed on tumor cells.1


LIBTAYO can help restore T-cell activity
T-cell activity restored

LIBTAYO binds to PD-1 on T cells, blocking its interaction with PD-L1 and PD-L2 on tumor cells, helping to restore the antitumor T-cell response.1

  • IgG4=immunoglobulin G4; PD-1=programmed death receptor-1; PD-L1=programmed death ligand 1; PD-L2=programmed death ligand 2. 

References: 1. LIBTAYO (cemiplimab-rwlc) injection full U.S. prescribing information. Regeneron Pharmaceuticals, Inc., and sanofi-aventis U.S. LLC. 2. Burova E, Hermann A, Waite J, et al. Characterization of the anti–PD-1 antibody REGN2810 and its antitumor activity in human PD-1 knock-in mice. Mol Cancer Ther. 2017;16(5):861-870. 3. Never accept the status quo: R&D excellence in the biotech industry. Regeneron Pharmaceuticals, Inc. website. https://www.regeneron.com/technology. Accessed November 19, 2020.